Ranitidine and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Ranitidine
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed buprenorphine (an opioid) along with ranitidine. The concern here is that ranitidine may slow down how your body breaks down buprenorphine, which can cause the opioid to build up in your blood. That can lead to stronger and longer-lasting opioid effects, like heavy drowsiness or, more seriously, slowed breathing.
The good news is this is very manageable. Your care team can adjust your buprenorphine dose and keep a closer eye on you. Please don't stop or change either medicine on your own. Just talk with your pharmacist or doctor, and watch for unusual sleepiness or trouble breathing.
Effect: Increased buprenorphine exposure via inhibition of CYP3A4-mediated metabolism, raising risk of prolonged opioid effects including sedation and respiratory depression.
- Direction: Ranitidine (a weak CYP3A4 inhibitor) increases buprenorphine plasma concentrations. Buprenorphine is not a prodrug, so effect is potentiated.
- Evidence: Probable; severity rated major. Onset unspecified.
- Management: If the inhibitor is needed, consider reducing the buprenorphine dose until stable effects are achieved; monitor frequently for sedation and respiratory depression. On inhibitor discontinuation, consider a dose increase and monitor for withdrawal. For subQ/long-acting formulations that cannot be finely titrated, monitor for over-medication or transition to a formulation permitting precise adjustment.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Because plasma buprenorphine concentrations rise when buprenorphine and a CYP3A4 inhibitor are taken together, extended opioid effects such as respiratory depression can result. Should a patient on buprenorphine require a CYP3A4 inhibitor, consider lowering the buprenorphine dose until drug effects stabilize, with frequent monitoring for sedation and respiratory depression. Conversely, when a CYP3A4 inhibitor is stopped in a patient on buprenorphine, consider raising the buprenorphine dose until stable drug effects are reached, and watch for indications of opioid withdrawal2. When dose adjustment is not feasible once the CYP3A4 inhibitor is gone, switch the patient back to a buprenorphine formulation that allows finer dose titration. For patients transitioned from transmucosal buprenorphine taken with CYP3A4 inhibitors, confirm through monitoring that the plasma buprenorphine level achieved with subQ buprenorphine is sufficient. For patients already receiving subQ buprenorphine who need a CYP3A4 inhibitor, monitor for indications of over-medication. If signs and symptoms of buprenorphine toxicity or overdose develop and the concomitant drug cannot be lowered or stopped, decrease the buprenorphine dose. When the available doses cannot deliver the intended dose, stop treatment and manage the patient with a buprenorphine formulation permitting more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. Here is what a team typically does:
- Your buprenorphine dose may need to be adjusted and individualized while you are on ranitidine, and adjusted again if ranitidine is stopped.
- Your team may monitor you more closely for sedation or slowed breathing while both are used, and for withdrawal signs when the inhibitor is stopped.
- With long-acting (injectable) buprenorphine that can't be finely dosed, your team may watch for over-medication or switch to a form that allows precise adjustment.
Tell your pharmacist or prescriber about all your medicines, and report unusual drowsiness, confusion, or breathing changes right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Studies have not examined how coadministered CYP3A4 inhibitors affect buprenorphine exposure in patients receiving subQ buprenorphine; nevertheless, these interactions have been documented in studies that used transmucosal buprenorphine. Buprenorphine's effects may vary according to the route by which it is administered 1.
Common questions
Can I take Ranitidine and Buprenorphine together?
Ranitidine can raise buprenorphine levels and prolong opioid effects like sedation and slowed breathing. Don't change anything yourself; your care team can manage this by adjusting your dose and monitoring you more closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Ranitidine and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Ranitidine and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. Here is what a team typically does: Your buprenorphine dose may need to be adjusted and individualized while you are on ranitidine, and adjusted again if ranitidine is stopped. Your team may monitor you more closely for sedation or slowed breathing while both are used, and for withdrawal signs when the inhibitor is… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Ranitidine or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Ranitidine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist